Silicon Therapeutic’s (STX) mission is to design novel therapeutics for the advancement of human health by building the most accurate in silico models of highly implicated human drug targets. STX has developed its own proprietary In Silico Targeted Engineering (INSITE) platform around this goal. Currently, we are applying the INSITE platform against target proteins that experience significant conformational change, which often renders them inaccessible to traditional drug discovery methods. STX plans to maintain scientific leadership in the field by first continuing to improve the science behind the INSITE platform, in addition to applying the INSITE platform to drive STX’s pipeline toward the clinic.